

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Horizon Health Limited

諾輝健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6606)

**(1) INSIDE INFORMATION: APPLICATION FOR APPOINTMENT OF
PROVISIONAL LIQUIDATORS;
(2) THE FIFTH QUARTERLY UPDATE ON RESUMPTION PROGRESS;
AND
(3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) (a) and Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated March 28, 2024 in relation to the suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on March 28, 2024; (ii) the announcement of the Company dated March 28, 2024 in relation to, among others, the delay in publication of the 2023 Annual Results; (iii) the announcement of the Company dated April 8, 2024 in relation to, among others, the establishment of the Independent Special Committee; (iv) the announcement of the Company dated May 28, 2024 on the Initial Resumption Guidance from the Stock Exchange; (v) the announcement of the Company dated June 28, 2024 in relation to the first quarterly update on resumption progress; (vi) the announcement of the Company dated September 9, 2024 in relation to the resignation of the Company’s auditor; (vii) the announcement of the Company dated September 27, 2024 in relation to the appointment of a new auditor of the Company; (viii) the announcement of the Company dated September 27, 2024 in relation to, among others, the second quarterly update on resumption progress; (ix) the announcement

of the Company dated September 27, 2024 in relation to, among other things, the change in composition of the Independent Special Committee; (x) the announcement of the Company dated December 27, 2024 in relation to the third quarterly update on resumption progress; (xi) the announcement of the Company dated January 6, 2025 in relation to the resignation of an Independent Non-executive Director and non-compliance with Rule 3.21 of the Listing Rules; (xii) the announcement of the Company dated January 9, 2025 in relation to the additional resumption guidance from the Stock Exchange; (xiii) the announcement of the Company dated March 10, 2025 in relation to the latest Resumption Guidance from the Stock Exchange; (xiv) the announcement of the Company dated March 28, 2025 in relation to the fourth quarterly update on resumption progress; (xv) the announcement of the Company dated April 14, 2025 in relation to the resignation of Independent Non-executive Directors (collectively, the “**Announcements**”).

Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the Announcements.

APPLICATION FOR THE APPOINTMENT OF JOINT PROVISIONAL LIQUIDATORS

On July 3, 2025, the Company submitted an application regarding appointment of joint provisional liquidators (“**JPLs**”) over the Company (the “**JPL Application**”) together with a winding up petition (the “**Petition**”) to the Grand Court of the Cayman Islands (the “**Grand Court**”) and is currently awaiting the Grand Court to assign a judge to hear the case before the JPL Application and Petition can be formally filed with the Grand Court. The Company considers that the JPL Application is in the best interest of the Shareholders and its creditors. The Company will make a further announcement once the JPL Application and Petition are filed.

Under the JPL Application, the Company has requested that the JPLs shall be given, among others, the powers to conduct investigations into the Company’s affairs, to carry on the business of the Company, to formulate a viable restructuring plan to enable the Company to continue as a going concern, to communicate and liaise with all relevant regulators and authorities on behalf of the Company for any necessary regulatory actions and to fulfil any listing requirements as may be necessary.

Further announcements will be made as soon as practicable to update the Shareholders on the development of the Petition and the JPL Application.

UPDATE ON PROGRESS OF RESUMPTION

Set out below is the latest Resumption Guidance and a further update on the progress of resumption:

Resumption Guidance

Update on Resumption Progress

- | | |
|--|--|
| (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications | The 2023 Annual Results and the 2024 Annual Results have yet to be finalized. |
| (ii) conduct an appropriate independent forensic investigation into the audit issues (including (a) the Audit Identified Issues; (b) allegations in two short-selling reports against the Group published in 2023; and (c) additional issues raised by the Auditor in relation to the Audit Identified Issues) for each financial year ended from December 31, 2021 to December 31, 2024, announce the findings, assess the impact and take appropriate remedial actions | As at the date of this announcement, the Investigation remains to be concluded in respect of the Modified Resumption Guidance. |
| (iii) demonstrate that there is no reasonable regulatory concern about the management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence | The Company's management and operations will be managed and controlled by the JPLs following their appointment. |
| (iv) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to comply with the Listing Rules | As at the date of this announcement, the IC Review has yet to be concluded. |

Resumption Guidance

- (v) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules
- (vi) re-comply with Rule 3.21 of the Listing Rules
- (vii) demonstrate that the Company is suitable for continued listing
- (viii) inform the market of all material information for the Shareholders and other investors to appraise its position

Update on Resumption Progress

The JPLs will review the Company's compliance with Rule 13.24 of the Listing Rules following their appointment.

As disclosed in the Company's announcement dated March 9, 2025, following the appointment of Dr. Yang Wang as an independent non-executive director and the change in composition of the Audit Committee with effect from March 10, 2025, the Audit Committee comprises three members and two of them are independent non-executive directors. Accordingly, the Company has re-complied with Rule 3.21 of the Listing Rules.

The JPLs will review the Company's suitability for continued listing following their appointment.

Since the suspension of trading in the Company's shares on March 28, 2024, the Company has kept its Shareholders and potential investors informed of all material information.

The Company will continue to keep its Shareholders informed of any relevant material development by making further announcement(s) as and when appropriate in accordance with the requirements under the Listing Rules.

CONTINUED SUSPENSION OF TRADING

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended until further notice.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
New Horizon Health Limited
Mr. Naxin Yao
Chairman

Hong Kong, July 4, 2025

As at the date of this announcement, the Board comprises Mr. Naxin YAO as Chairman and non-executive Director, Dr. Yiyou CHEN as executive Director, and Mr. Danke YU, Ms. Jiangnan KONG and Dr. Yang WANG as independent non-executive Directors.